Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The fibroblast growth factor (FGF)/FGF receptor (FGFR) pathway is implicated in cancer progression, including tumor growth, angiogenesis, and therapeutic resistance.
• The soluble pattern recognition receptor, long-pentraxin 3 (PTX3), functions as a multi-FGF antagonist, suggesting potential anti-cancer roles.

Purpose of the Study:

• To investigate the therapeutic potential of PTX3 and its derivatives in inhibiting FGF-driven tumor progression.
• To identify small molecules that can trap FGFs extracellularly for cancer therapy.

Main Methods:

• Overexpression of human PTX3 in transgenic mice under the Tie2 promoter.
• Evaluation of tumor growth, angiogenesis, and metastasis in various FGF-dependent tumor models (heterotopic, orthotopic, autochthonous).
• Pharmacophore modeling to understand the interaction between a PTX3-derived pentapeptide and FGF2, leading to the identification of a small-molecule inhibitor (NSC12).

Main Results:

• PTX3 overexpression significantly inhibited tumor growth, angiogenesis, and metastasis in preclinical cancer models.
• The study identified NSC12, a small molecule derived from pharmacophore modeling, which acts as an effective extracellular FGF trap.
• These findings highlight the therapeutic potential of targeting the FGF pathway via PTX3 or small-molecule FGF traps.

Conclusions:

• PTX3 is a potent inhibitor of tumor growth, angiogenesis, and metastasis, mediated through its antagonism of FGF signaling.
• NSC12 represents a promising novel therapeutic strategy for cancer by sequestering FGFs extracellularly.
• Targeting the FGF pathway with PTX3 or small-molecule FGF traps holds significant therapeutic implications for cancer treatment.